On September 1, 2026 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.
Sana will present at Citi’s 2026 Biopharma Back-to-School Conference at 1:40 p.m. ET on Thursday, September 10, 2026.
Sana will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 14, 2026.
Sana will present at the HC Wainwright 28th Annual Global Investment Conference at 11:30 a.m. ET on Tuesday, September 15, 2026.

The webcasts will be accessible on the Investor Relations page of Sana’s website at View Source A replay of each presentation will be available at the same location for 30 days following the conference.

(Press release, Sana Biotechnology, SEP 1, 2026, View Source [SID1234670495])

On September 1, 2026 Exelixis, Inc. (Nasdaq: EXEL) reported that company management will participate in fireside chats at the following investor conferences in September:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston.
Citi 2026 Biopharma Back to School Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Wednesday, September 9 in New York City.
Morgan Stanley 24th Annual Global Healthcare Conference: Exelixis is scheduled to present at 11:30 a.m. ET / 8:30 a.m. PT on Tuesday, September 15 in New York City.
To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

(Press release, Exelixis, SEP 1, 2026, View Source [SID1234670494])

On September 1, 2026 BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, reported that members of its management team will participate in fireside chats at the following healthcare investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT
2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT
Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT
Bernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT

To access the live webcast of BridgeBio’s presentations, please visit the "Events and Presentations" page within the Investors section of the BridgeBio website at View Source A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

(Press release, BridgeBio, SEP 1, 2026, View Source [SID1234670493])

On September 1, 2026 Domainex, a leading integrated drug discovery services partner, and Vipergen, a pioneering DNA-encoded library (DEL) screening company, reported a strategic collaboration to support lead discovery programmes across a range of disease targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the collaboration, clients can now access Vipergen’s DEL screening capabilities alongside Domainex’s expertise in assay development, biophysics, medicinal chemistry, and integrated discovery services – providing a seamless, end-to-end solution from hit identification to validated leads.

A first client case study has already shown the partnership in action: Vipergen’s DEL screening platform identified novel molecular glue hits, and Domainex independently confirmed them through complementary biophysics and assay development work.

"This collaboration expands the range of hit and lead discovery solutions available to our clients by combining Vipergen’s unique DEL screening technology with Domainex’s established fragment-based and high-throughput screening (HTS) approaches, as well as our assay development, biophysics, and medicinal chemistry expertise. Together, we can help partners identify, validate, and progress high-quality starting points for their drug discovery programmes," said Dr Hayley French, CEO of Domainex.

"We are thrilled to partner with Domainex, whose broad and complementary drug discovery capabilities make them an ideal partner for Vipergen. This collaboration allows us to offer clients a truly integrated path from DEL screening hits to optimised leads – combining the unique advantages of our cell-based and in vitro DEL platforms with Domainex’s world-class assay and medicinal chemistry expertise," said Dr Nils Hansen, CEO of Vipergen.

Together, the two companies provide a complementary suite of technologies and expertise designed to streamline the transition from hit identification to validated lead series, helping accelerate early-stage drug discovery programmes.

(Press release, Vipergen, SEP 1, 2026, View Source [SID1234670492])

On September 1, 2026 SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, reported that the company will participate in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

12th Cantor Global Healthcare Conference in New York City
Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference in New York City
1×1 investor meetings: September 14-16, 2026

A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the event.

(Press release, Scynexis, SEP 1, 2026, View Source [SID1234670491])